BMC Cell Biology · 2009 · 92 citations · 57 references
Life SciencesCell BiologyMolecular BiologyCell SignalingEndocytosisSignal TransductionCancer Cell SignalingEndosomal SortingEndosomal TraffickingLate EndosomesOncogenic Signaling PathwaysReceptor-mediated EndocytosisEndocytic InternalizationEndocytic Pathway RegulationEndocytic Recycling PathwaysEndocytic RegulationEndocytic Trafficking Of ReceptorsEpidermal Growth Factor Receptor EndocytosisKinase Domain MutationsRab11-mediated Endocytic Recycling
BACKGROUND: Epidermal growth factor receptor (EGFR) controls a wide range of cellular processes, and altered EGFR signaling contributes to human cancer. EGFR kinase domain mutants found in non-small cell lung cancer (NSCLC) are constitutively active, a trait critical for cell transformation through activation of downstream pathways. Endocytic trafficking of EGFR is a major regulatory mechanism as ligand-induced lysosomal degradation results in termination of signaling. While numerous studies have examined mutant EGFR signaling, the endocytic traffic of mutant EGFR within the NSCLC milieu remains less clear. RESULTS: This study shows that mutant EGFRs in NSCLC cell lines are constitutively endocytosed as shown by their colocalization with the early/recycling endosomal marker transferrin and the late endosomal/lysosomal marker LAMP1. Notably, mutant EGFRs, but not the wild-type EGFR, show a perinuclear accumulation and colocalization with recycling endosomal markers such as Rab11 and EHD1 upon treatment of cells with endocytic recycling inhibitor monensin, suggesting that mutant EGFRs preferentially traffic through the endocytic recycling compartments. Importantly, monensin treatment enhanced the mutant EGFR association and colocalization with Src, indicating that aberrant transit through the endocytic recycling compartment promotes mutant EGFR-Src association. CONCLUSION: The findings presented in this study show that mutant EGFRs undergo aberrant traffic into the endocytic recycling compartment which allows mutant EGFRs to engage in a preferential interaction with Src, a critical partner for EGFR-mediated oncogenesis.
57
<i>EGFR</i> Mutations in Lung Cancer: Correlation with Clinical Response to Gefitinib Therapy
J. Guillermo Paez, Pasi A. Jänne, Jeffrey C. Lee et al. · Science · 2004 · 9.4K citations
An Allosteric Mechanism for Activation of the Kinase Domain of Epidermal Growth Factor Receptor
Xuewu Zhang, Jodi Gureasko, Kui Shen et al. · Cell · 2006 · 1.6K citations · Full text
Gefitinib-Sensitizing <i>EGFR</i> Mutations in Lung Cancer Activate Anti-Apoptotic Pathways
Raffaella Sordella, Daphne W. Bell, Daniel A. Haber et al. · Science · 2004 · 1.6K citations
Medicine, Oncology, Pharmacology +17